Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-023-05163-z
Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany Ralph Wäsch, Tim Strüssmann, Claudia...
Conclusions/Relevance: Our case illustrates the feasibility of CAR T-cell therapy in MM patients with end-stage renal disease on hemodialysis, thus warrants more MM patients not to be excluded from this valuable cell therapy approach.
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36907717/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Our results showed that low-dose or short-time use of G-CSF was not associated with the incidence or severity of CRS or NEs, and G-CSF administration did not influence the antitumor activity of CAR T-cell therapy.
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36902326/
The study of osteoblast (OB) metabolism has recently received increased attention due to the considerable amount of energy used during the bone remodeling process. In addition to glucose, the main...
Conclusion: We describe the main metabolic pathways governing OBs' fate and functions, both in physiological and pathological malignant conditions. In particular, we focus on multiple myeloma (MM) bone disease, which is characterized by a severe imbalance in OB differentiation due to the presence of malignant plasma cells into the bone...
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma - Leukemia
Source : https://www.nature.com/articles/s41375-023-01824-0
Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a case study on pulmonary flare-up after Idecabtagen Vicleucel (Ide-cel),...
Conclusion: Our study highlights a Th17.1 driven autoimmune phenomenon after CAR T, which may be misinterpreted as disease relapse, and that imaging with multiple PET tracers and scRNA-seq could help in this diagnostic dilemma.
Peripheral Nerve Stimulation for Back Pain in Patients With Multiple Myeloma as Bridge Therapy to Radiation Treatment: A Case Series
Source : https://www.neuromodulationjournal.org/article/S1094-7159(23)00027-2/fulltext
Patients with spinal lesions or vertebral compression fractures from multiple myeloma often present with back pain that restricts their ability to lie flat and prevents them from undergoing cancer treatment....
Conclusions: PNS can effectively treat low back pain secondary to myeloma-related spinal lesions as a bridge therapy to radiation. The use of PNS is a promising option for back pain from other primary or metastatic tumors. Further research is needed into the use of PNS for cancer-related back pain.